|
Reason for the notification
|
|
|
Initial
notification /Amendment
|
Initial
notification
|
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Name
|
Smith
& Nephew plc
|
|
LEI
|
213800ZTMDN8S67S1H61
|
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
|
Description
of the financial instrument, type of instrument
|
Smith
& Nephew plc ordinary shares of USD 0.20 each
|
|
Identification
code
|
ISIN:
GB0009223206
|
|
Nature
of the transaction
|
Purchase
of ordinary shares through the Company's Dividend Re-Investment
Plan following the 2025 interim dividend payment on 7 November
2025.
|
|
Date of
Transaction
|
2025 -
11 - 07
|
|
Place
of Transaction
|
London
Stock Exchange (XLON)
|
|
Name
(Position)
|
Director / PDMR
|
Price (£)
|
Volume
|
Aggregated information
|
|
Scott
Schaffner
(President,
Sports Medicine)
|
PDMR
|
12.4048
|
746.79305
|
N/A
Single Transaction
|
|
Deepak
Nath
(Chief
Executive Officer)
|
Director
|
12.4048
|
2624.43651
|
N/A
Single Transaction
|
|
Rohit
Kashyap (President, Advanced Wound Management and Global Commercial
Operations)
|
PDMR
|
12.4048
|
427.09066
|
N/A
Single Transaction
|
|
Craig
Gaffin
(President,
Orthopaedics)
|
PDMR
|
12.4048
|
197.25944
|
N/A
Single Transaction
|
|
Mizanu
Kebede
(Chief
Quality & Regulatory Affairs Officer)
|
PDMR
|
12.4048
|
4.1729
|
N/A
Single Transaction
|
|
Paul
Connolly
(President,
Global Operations)
|
PDMR
|
12.4048
|
394.41542
|
N/A
Single Transaction
|
|
|
|
|
|
|
|
Smith & Nephew plc
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
Date:
November 10, 2025
|
By:
|
/s/
Helen Barraclough
|
|
|
|
Helen
Barraclough
|
|
|
|
Company
Secretary
|